About Us

OnCuRNA is a preclinical-stage oncology company advancing the SANG platform, a nanohydrogel technology designed to optimize drug delivery to solid tumors and minimize the serious toxicities associated with current cancer treatments. Our proprietary nanohydrogel drug delivery platform outperforms traditional lipid-based nanoparticle systems, providing a more effective and precise approach to targeting tumors. With a focus on translational science, we aim to bring groundbreaking therapies from the lab to the clinic, improving outcomes for patients worldwide.